Financial Highlights & Revenue Break Up

Financial Highlights & Revenue Break Up

35,000

30,000

25,000

20,000

10,000

5,000

0

22,792

FY 19

25,986

FY 20

32,375

FY 21

Revenue

35%

30%

25%

15%

10%

5%

0%

16.8%

FY 19

20.2%

FY 20

26.4%

FY 21

EBITDA %

9,000

7,500

6,000

4,500

3,000

1,500

0

3,840

FY 19

5,253

FY 20

8,552

FY 21

EBITDA

7,000

6,000

5,000

3,000

2,500

2,000

0

2,364

FY 19

3,355

FY 20

5,495

FY 21

PAT

23%

19%

14%

9%

6%

3%

0%

10.4%

FY 19

12.9%

FY 20

17.0%

FY 21

PAT%

26,000

22,000

18,000

15,000

10,000

5,000

0

15,295

FY 19

18,437

FY 20

21,732.74

FY 21

Networth

30,000

25,000

20,000

15,000

10,000

5,000

0

14,729

FY 19

18,752

FY 20

21451.49

FY 21

Gross Block

Break-up of Consolidated Revenue as per Geography

FY'21 (Rs. in Mn)
17,451

54%

5,674

18%

2,925

9%

4,525

14%

1,800

6%

North America
Europe
Row
Latin America
India

Break-up of Consolidated Revenue as per Business Segment

FY'21 (Rs. in Mn)
16,989

53%

9,124

28%

6,262

19%

PFI
API
FD

Break-up of Consolidated Revenue as per Molecule

FY'21 (Rs. in Mn)
10,939

34%

8,498

26%

5,808.2

18%

1,051.7

3%

928.6

3%

5,150

16%

Paracetamol
Metformin
Guaifenesin
Ibuprofen
Methocarbamol
Others

Break-up of Consolidated Revenue as per Business Segment

FY'20 (Rs. in Mn)
13,602

52%

8,170

31%

4,214

16%

API
PFI
FD